Adrenomyeloneuropathy (AMN)
https://pmc.ncbi.nlm.nih.gov/articles/PMC11706703/#jimd12845
Adrenoleukodystrophy (ALD) is a genetic disorder that can affect the spinal cord, leading to mobility and sensory issues. This study followed 79 adult men with ALD over 7 years to understand how spinal cord disease progresses in this condition and is the longest follow up study in this cohort to date. ALD often leads to a condition called adrenomyeloneuropathy (AMN), which causes symptoms such as bladder problems, walking difficulties, and sensory issues. Researchers used tests like the Expanded Disability Status Scale (EDSS) and Severity Score System for Progressive Myelopathy (SSPROM) which shows severity of the disease, a 6 minute walking test (6MWT), and quality of life questionnaires to track changes over time. The results showed that disability worsened gradually and predictably. The study also found that 50% of patients developed spinal cord symptoms by age 50, with sensory changes like reduced vibration sense often being an early sign. Interestingly, urinary symptoms and quality of life scores did not change significantly over time, suggesting these measures may not be sensitive enough to track disease progression. Psychological concerns were more common in middle-aged patients, emphasising the need for mental health support. The study also found that spinal cord damage often begins with sensory loss, supporting earlier research. This research provides important insights for designing clinical trials and counselling patients while highlighting the need for better ways to track disease progression. Current clinical trial measures require long follow-up periods and many participants. New, more sensitive tests—such as body sway analysis—may help detect changes earlier, allowing for better treatment strategies in the future.